Oxford BioDynamics (LON:OBD) Reaches New 1-Year Low – Time to Sell?

Oxford BioDynamics Plc (LON:OBD) shares reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as GBX 0.20 and last traded at GBX 0.22, with a volume of 4227599 shares changing hands. The stock had previously closed at GBX 0.22.

Oxford BioDynamics Stock Up 2.3%

The company has a current ratio of 0.88, a quick ratio of 2.80 and a debt-to-equity ratio of 457.97. The stock has a market cap of £9.44 million, a P/E ratio of -0.28 and a beta of 0.42. The firm has a 50-day simple moving average of GBX 0.27 and a two-hundred day simple moving average of GBX 0.32.

Oxford BioDynamics (LON:OBD) last posted its earnings results on Wednesday, December 24th. The biotechnology company reported GBX (0.80) earnings per share for the quarter. Oxford BioDynamics had a negative return on equity of 316.67% and a negative net margin of 1,018.54%.

Oxford BioDynamics Company Profile

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.